Pharmaceutical Clinical Research Associates (CRAs) are critical members of the drug development team responsible for managing and monitoring clinical trials that test new medications for safety and efficacy. They ensure that trials are conducted in compliance with regulatory standards such as Good Clinical Practice (GCP) and study protocols. CRAs regularly visit clinical trial sites to verify the accuracy of collected data, confirm that patients meet eligibility criteria, and ensure informed consent has been properly obtained. By meticulously reviewing case report forms against source documents, they help maintain data integrity and protect patient safety throughout the study. Their monitoring activities are essential to producing reliable and valid results for regulatory review.
In addition to site monitoring, CRAs serve as a communication link between pharmaceutical sponsors, clinical investigators, and regulatory authorities. They provide ongoing support and training to clinical site personnel to uphold quality standards and regulatory compliance. CRAs also prepare monitoring visit reports and assist in the preparation of documentation required for audits and inspections. Strong attention to detail, excellent organizational skills, and the ability to manage multiple sites are crucial attributes for success in this role. Ultimately, CRAs help ensure that clinical trials are conducted ethically and efficiently, contributing to the development of new therapies that improve patient outcomes globally.
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami, United States
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N D Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : R&D consultancy at the medicines discovery catapult: De-risking drug discovery for innovators
Adriana Gambardella, Medicine Discovery Catapult, United Kingdom
Title : Biocompatible synthesis of non crystalline iron oxide nanoparticles with stable colloidal properties
Lan Wang, Paretor LLC, United States
Title : Hydrogen sulfide in sepsis: From bench to bedside
Madhav Bhatia, University of Otago, New Zealand
Title : Biocompatibility and subcutaneous host response to silk fibroin–chitosan composite plugs: Progress toward biodegradable implant materials
Luis Jesus Villarreal Gomez, Universidad Autónoma de Baja California, Mexico